These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33221932)

  • 41. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil.
    Jardim AV; Jardim DV; Chaves BR; Steglich M; Ot'alora G M; Mithoefer MC; da Silveira DX; Tófoli LF; Ribeiro S; Matthews R; Doblin R; Schenberg EE
    Braz J Psychiatry; 2021; 43(2):181-185. PubMed ID: 32638920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review of potential psychedelic treatments for PTSD.
    Henner RL; Keshavan MS; Hill KP
    J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine-Assisted Therapy for Posttraumatic Stress Disorder: A Review of the Evidence, Neurobiological Plausibility, and Clinical Significance.
    Price CM; Feduccia AA; DeBonis K
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):464-469. PubMed ID: 36018231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.
    Spangler PT; West JC; Dempsey CL; Possemato K; Bartolanzo D; Aliaga P; Zarate C; Vythilingam M; Benedek DM
    J Clin Psychiatry; 2020 Oct; 81(6):. PubMed ID: 33113596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder.
    Sessa B; Higbed L; O'Brien S; Durant C; Sakal C; Titheradge D; Williams TM; Rose-Morris A; Brew-Girard E; Burrows S; Wiseman C; Wilson S; Rickard J; Nutt DJ
    J Psychopharmacol; 2021 Apr; 35(4):375-383. PubMed ID: 33601929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in service personnel.
    Cipriani A; Cowen PJ
    Lancet Psychiatry; 2018 Jun; 5(6):453-455. PubMed ID: 29728332
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a Psychotherapeutic Setting.
    Corey VR; Pisano VD; Halpern JH
    J Nerv Ment Dis; 2016 Jul; 204(7):519-23. PubMed ID: 26998697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.
    Oeri HE
    J Psychopharmacol; 2021 May; 35(5):512-536. PubMed ID: 32909493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.
    Van Leeuwen E; van Driel ML; Horowitz MA; Kendrick T; Donald M; De Sutter AI; Robertson L; Christiaens T
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013495. PubMed ID: 33886130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder.
    Amoroso T
    J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.
    Baldo BA
    Arch Toxicol; 2024 Aug; 98(8):2409-2427. PubMed ID: 38743292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.
    Sessa B; Sakal C; O'Brien S; Nutt D
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31308191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.
    Varker T; Watson L; Gibson K; Forbes D; O'Donnell ML
    J Psychoactive Drugs; 2021; 53(1):85-95. PubMed ID: 32931403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics".
    Sessa B
    Neurosci Lett; 2017 May; 649():176-180. PubMed ID: 27394687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Double-Blind, Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder and Comorbid Depression.
    Ramaswamy S; Driscoll D; Reist C; Smith LM; Albers LJ; Rose J; Nguyen L; Monga V; Doria R; Hollifield M
    Prim Care Companion CNS Disord; 2017 Aug; 19(4):. PubMed ID: 28858440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example.
    Wagner AC; Mithoefer MC; Mithoefer AT; Monson CM
    J Psychoactive Drugs; 2019; 51(2):166-173. PubMed ID: 30890035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder.
    Robert S; Hamner MB; Ulmer HG; Lorberbaum JP; Durkalski VL
    J Clin Psychiatry; 2006 Oct; 67(10):1522-6. PubMed ID: 17107242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale.
    Johansen PØ; Krebs TS
    J Psychopharmacol; 2009 Jun; 23(4):389-91. PubMed ID: 19273493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.